GRAFT POLYMER UK LS -001 Cash Flow Conversion Efficiency

Latest as of November 2024: -0.048x

GRAFT POLYMER UK LS -001 cash flow conversion efficiency. Based on the latest financial reports, GRAFT POLYMER UK LS -001 (J4I) has a cash flow conversion efficiency ratio of -0.048x as of November 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-149.00K ≈ $-174.20K USD) by net assets (€3.08 Million ≈ $3.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of GRAFT POLYMER UK LS -001 (2023–2026)

Cash flow conversion efficiency of GRAFT POLYMER UK LS -001 from 2023 to 2026. This chart illustrates how GRAFT POLYMER UK LS -001's cash flow conversion efficiency has evolved over time, based on yearly financial data. View J4I stock price and chart for real-time trading data and today's change.

GRAFT POLYMER UK LS -001 Cash Flow Conversion Ratio Explained

GRAFT POLYMER UK LS -001 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

GRAFT POLYMER UK LS -001 Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GRAFT POLYMER UK LS -001 ranked by their cash flow conversion efficiency. Also see market cap of GRAFT POLYMER UK LS -001 for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Visgeneer
TWO:4197
-0.062x
iTonic Holdings Ltd.
NASDAQ:ITOC
-0.050x
Cerberus Cyber Sentinel Corp
NASDAQ:CISO
-0.006x
Ascelia Pharma AB (publ)
ST:ACE
-0.137x
Cohort
LSE:CHRT
0.229x
Millennium Silver Corp
V:MSC
0.019x
Lite Access Technologies Inc
V:LTE
1.235x
Biomerica Inc
NASDAQ:BMRA
-0.347x

Annual Cash Flow Conversion Efficiency for GRAFT POLYMER UK LS -001 (2023–2026)

The table below shows the annual cash flow conversion efficiency of GRAFT POLYMER UK LS -001 from 2023 to 2026. Review J4I free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2026-05-31 €6.19 Million
≈ $7.24 Million
€-3.27 Million
≈ $-3.83 Million
-0.529x -44.28%
2025-05-31 €3.08 Million
≈ $3.61 Million
€-1.13 Million
≈ $-1.32 Million
-0.366x +40.04%
2024-05-31 €2.03 Million
≈ $2.37 Million
€-1.24 Million
≈ $-1.45 Million
-0.611x -17.91%
2023-05-31 €4.55 Million
≈ $5.32 Million
€-2.36 Million
≈ $-2.76 Million
-0.518x --

About GRAFT POLYMER UK LS -001

F:J4I Germany Biotechnology
Market Cap
$9.24 Million
€7.90 Million EUR
Market Cap Rank
#27515 Global
#2359 in Germany
Share Price
€0.00
Change (1 day)
+0.00%
52-Week Range
€0.00 - €0.00
All Time High
€0.25
About

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre… Read more